Clinical Efficacy Observation of Low-Dose Methylprednisolone Sodium Succinate Combined with Human Immunoglobulin in the Treatment of Severe Pneumonia in Children

HUANG Yaomi; OU Yangjie

doi:10.13919/j.issn.2095-6274.ZHJY202502025

Abstract：Objective To explore the value of a treatment regimen involving low-dose methylpredniso-lone sodium succinate combined with human immunoglobulin for children with severe pneumonia.Methods A retrospective study was conducted involving 56 children with severe pneumonia admitted to the People's Hospital of Anshun,Guizhou Province,from June 2022 to June 2024.The patients were divided into two groups based on the use of human immunoglobulin:the study group(28 cases,treated with methylprednisolone sodium succinate combined with human immunoglobulin)and the control group(28 cases,treated with methylprednisolone sodium succinate alone).The clinical symptoms and signs improvement time,immunoglobulin levels,inflammatory factors,pulmonary function indicators,clinical efficacy,and incidence of adverse events were compared between the two groups.Results Compared to the control group,the study group showed significantly shorter fever resolution time,disappearance of lung rales,cough resolution time,wheezing resolution time,absorption time of lung con-solidation,and hospitalization time(P＜0.001).Before treatment,there were no significant differences between the two groups in immunoglobulin(IgA,IgG,IgM),inflammatory factors C-reactive protein(CRP),tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),or pulmonary function indicators such as forced expiratory volume in 1 second(FEV1),forced vital capacity(FVC),and the FEV1/FVC ratio(P＞0.05).After treatment,both groups showed significant improvements in immunoglobulin and pulmonary function levels(P＜0.05).The study group showed more pronounced increases in IgA(P＜0.001),IgG(P＜0.05),IgM(P＜0.05),FEV1(P＜0.05),FVC(P＜0.001),and FEV1/FVC(P＜0.001).Inflammatory markers showed a significant decrease(P＜0.05),with the study group showing more significant reductions in CRP(P＜0.001),TNF-α(P＜0.001),and IL-6(P＜0.001).The clinical total effective rate was significantly higher in the study group compared to the control group(96.43％vs.75.00％,P＜0.05).The overall incidence of adverse events was similar between the two groups(17.86％vs.10.71％,P＞0.05).Conclusion For children with severe pneumonia,a treat-ment regimen involving low-dose methylprednisolone sodium succinate combined with human immunoglobulin effectively shortens the time for clinical symptom improvement,enhances immune function,reduces inflammation,improves pulmonary function,and provides significant clinical efficacy with a relatively high safety profile.